سعر بريثوفانس محلول استنشاق 2.5 مل أمبولات 2026

Nebulizer solution combining ipratropium bromide and salbutamol; 20 ampoules of 2.5 ml.

• Directory: anti-asthma; treatment of respiratory crises and COPD.Population: Patients with asthma/COPD (specialist)
• US same-ingredient nebulizer combination: bronchodilation in COPD (and related labelled uses on US SPLs).Population: Adults with COPD (US labelled populations)DailyMed

• Hypersensitivity to any component, or to atropine and its derivatives (US combination nebulizer label).International label, equivalent formulation · DailyMed

• Paradoxical bronchospasm, cardiovascular effects, anticholinergic effects (urinary retention, glaucoma risk with eye exposure), hypokalemia — monitor per class labelling; specialist use.International label, equivalent formulation · DailyMed

• Albuterol sulfate historically Pregnancy Category C on US combination nebulizer labels (teratogenic in mice at high doses). Use only if benefit justifies risk.International label, equivalent formulation · DailyMed

• Ipratropium bromide: Blocks muscarinic receptors in bronchial smooth muscle, reducing vagally mediated bronchoconstriction; minimal systemic absorption when inhaled.
• Salbutamol: Stimulates beta-2 adrenergic receptors in airway smooth muscle, increasing cyclic AMP and causing bronchodilation.